The mosquito-borne Zika virus — described in recent, grim federal warnings as “not controllable by current technologies”— could become an important source of hope for a regrouped Novavax Inc.
Gaithersburg-based Novavax (NASDAQ: NVAX), still recovering from stunning negative results from its phase 3 trials of its lead respiratory syncytial virus (RSV) vaccine for older adults, said this week that it had “exciting preclinical data” from its new Zika program.
{iframe}http://www.bizjournals.com/washington/news/2016/11/11/how-the-zika-virus-could-be-a-major-bright-spot.html?ana=e_me_set1&s=newsletter&ed=2016-11-14&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1479141928&j=76453721{/iframe}